Real-world use of LC-OCT to help diagnose basal cell carcinoma
Official title: Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice: a Retrospective Observational Study
Run by Maastricht University Medical Center · NCT07501780 · Data updated 2026-11-12
This study tests how well LC-OCT works in everyday dermatology practice to help diagnose basal cell carcinoma without always needing a biopsy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 297 (estimated) |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 1 site (Maastricht, Limburg) |
| Status | Recruiting |
| Started | June 15, 2026 |
| Main results expected | August 15, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | October 19, 2026 |
| Trial ID | NCT07501780 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older who had LC-OCT as part of their diagnostic evaluation for suspected BCC at Maastricht University Medical Center or Mohs clinics between Jan 2025 and Jun 2025, with available histopathology and/or follow-up data.
✕Probably not a fit
Patients without histopathological confirmation or follow-up data, or those whose LC-OCT findings do not lead to changes in management, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, observational assessment conducted at Mohs clinics in the Netherlands to evaluate how LC-OCT is used in routine diagnostic workups for suspected basal cell carcinoma. It examines real-world diagnostic performance by comparing LC-OCT results with histopathology and clinical follow-up data collected between January and June 2025. The study aims to determine whether high-confidence LC-OCT diagnoses could reduce biopsy rates, speed treatment, and improve clinic efficiency. Results will inform the practicality and accuracy of integrating LC-OCT into standard care outside tightly controlled research settings. The analysis focuses on adults who underwent LC-OCT as part of their evaluation and had confirmatory pathology or follow-up data available.
Why it matters
Potential benefit: If successful, LC-OCT could reduce unnecessary biopsies and accelerate treatment for patients with high-confidence BCC diagnoses.
How similar studies have gone: Previous research reports high LC-OCT specificity and sensitivity in controlled settings, but real-world performance data are limited, making this study comparatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years * LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands * Histopathological results (biopsy or excision) and/or 6-12 month clinical follow-up data available Exclusion Criteria: * Patients \<18 years of age * Cases without histopathological confirmation or available follow-up data
Where it's running
-
Maastricht University Medical Center +
Maastricht, Limburg, Netherlands Recruiting
Study contacts
- Study coordinator: Yara Valkenburg, MD
- Email: yara.valkenburg@mumc.nl
- Phone: +31(0)43- 387 7295
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Multimodal Imaging Usability in Basal Cell Carcinoma
We’re testing how easy and quick three non-invasive imaging tools are for adults with basal cell carcinoma to use during a single visit.
-
Two-photon microscopy on skin biopsies to help diagnose skin lesions
This study tests whether images from two-photon fluorescence microscopy of dermatology biopsies can match the diagnosis determined by standard histology.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
Continuous Vital Sign Monitoring in a Gastro-surgical Ward
This study tests whether wearing sensors that continuously track vital signs helps detect deterioration earlier for adults on a gastro-surgical ward, in addition to standard NEWS-2 monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.